Flatiron’s LLM-enabled data extraction and rigorous validation have unlocked 505,000 patients with hematologic malignances, including rare patient cohorts with rich clinical detail at unprecedented scale

Flatiron Health, a leading healthtech company dedicated to improving cancer care and advancing research using real-world data, today announced the launch of six new hematology Panoramic datasets, representing another critical moment of scientific innovation that foundationally redefines the company's real-world evidence offerings in blood cancers. Flatiron’s Panoramic data unlocks the company’s entire patient network, leveraging breakthrough AI and large language model capabilities alongside their extensive database to extract and validate clinical data at unprecedented scale.

Over the past decade, Flatiron has created a research database including over five million patient records, unlocking more than 1.5 billion data points available for research. The new hematology Panoramic datasets, including five B-cell lymphomas and multiple myeloma, draw from over 505,000 relevant longitudinal patient records in Flatiron’s network. Through rigorous application of Flatiron's VALID data quality framework, the datasets maintain the company's gold-standard data quality and will enable life science companies to dramatically expand research access to rare patient populations and sub-cohorts of interest, addressing the totality of their evidence needs with one comprehensive solution.

"For more than a decade, Flatiron has been building and curating the world's most comprehensive real-world global oncology research database," said Nathan Hubbard, Chief Executive Officer of Flatiron Health. "These hematology datasets showcase what becomes possible when you combine our proven AI capabilities with our commitment to scientific rigor—the potential to deliver more precise, personalized treatments to patients with hematologic malignancies."

The six new hematology Panoramic datasets represent a six-fold increase in cohort sizes when compared to the company’s previously available datasets and reflect the current standard of care with enhanced clinical breadth and depth. The datasets' novel interoperability enable streamlined analysis of patients across B-cell lymphoma indications and insight into transformations along the full patient journey. These significant new offerings unlock life science companies’ and researchers' ability to study rare hematologic malignancy subgroups that have been historically underrepresented in clinical research, addressing critical gaps in blood cancer research.

"These new hematology datasets represent the culmination of product innovation focused on solving real problems that matter for our partners, like studying novel modalities, niche patient cohorts, and both the predictive and prognostic value of molecular response on patient outcomes," said Kate Estep, VP, Head of Product at Flatiron Health. “By integrating our AI-powered extraction capabilities with our proven data quality framework, we're not just delivering more data—we're delivering the right data at the scale our customers need, all while maintaining the rigorous data standards our partners depend on for regulatory-grade evidence.”

The datasets capture rich clinical details, including comprehensive coverage of molecular residual disease (MRD) testing and CAR-T therapy utilization—two critical components for understanding modern hematology treatment patterns, adherence, and outcomes. MRD testing data provides essential insights for assessing treatment response and monitoring, while CAR-T therapy information enables analysis of this revolutionary treatment's real-world implementation and effectiveness.

"Over the past five years we’ve witnessed remarkable breakthroughs in hematologic diseases—including next-generation immunotherapies like CAR T and bispecifics, precision-targeted therapies like menin inhibitors, and ultra-sensitive approaches to monitoring disease like MRD. The pace of these advances means we must also evolve how we generate real-world evidence by comprehensively capturing the clinical nuances and biologic complexity that define modern care," said Emily Castellanos, MD, MPH, Senior Medical Director and Head of Research Oncology at Flatiron Health. "From a clinical perspective, these datasets will transform research in this field because they reflect the true complexity of hematologic cancer care at a scale that simply wasn’t possible before. This evidence foundation will guide better treatment decisions, accelerate new development, and ultimately improve outcomes for patients with blood cancers."

The company's track record includes over 250 publications advancing understanding of blood cancer treatment and outcomes. With in-house hematology expertise spanning critical rare patient cohorts and novel therapies like CAR T, plus specialized analytics teams, Flatiron enables previously impossible analyses, supporting partners with:

• studies into highly specific patient cohorts like high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements or multiple myeloma with high-risk cytogenetics or extramedullary disease,
• fully characterizing the effectiveness and safety of novel therapies through a portfolio of endpoints including real-world progression, clinical and molecular response, and adverse events,
• gaining a holistic view into the patient journey by assessing use of IV, oral, and cellular therapies from inpatient and outpatient settings documented in unstructured data sources; and more.

More than 275 research acceptances across industry leading scientific conferences in 2025 demonstrate Flatiron's continued commitment to methodological innovation and scientific rigor. The company's presentations at ISPOR Europe this year showcase expertise in real-world evidence methodologies, while upcoming participation at ASH 2025 reinforces Flatiron's dedication to advancing hematology research through high-quality data and responsible AI applications.

About Flatiron

Flatiron Health is a healthtech company expanding the possibilities for point of care solutions in oncology and using data for good to power smarter care for every person with cancer. Through machine learning and AI, real-world evidence, and breakthroughs in clinical trials, we continue to transform patients’ real-life experiences into knowledge and create a more modern, connected oncology ecosystem. Flatiron Health is an independent affiliate of the Roche Group.

About Panoramic Data

Panoramic data is Flatiron's foundational real-world data, flexibly designed to meet the needs of biopharma’s evolving research priorities with biomarker depth, scaled outcomes, and longitudinal data across 5M+ patients. Panoramic data is a comprehensive data solution that spans disease settings and supports assessments of high priority subgroups of interest. Flatiron offers Panoramic data across solid tumors and hematologic malignancies to maximize use cases across oncology portfolios.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251029554140/en/

The new hematology Panoramic datasets, including five b-cell lymphomas and multiple myeloma, draw from over 505,000 relevant longitudinal patient records in Flatiron’s network.